RxDoctor Payments Data

Sam Martin, MD

Interventional Pain Medicine · Brentwood, MONPI 1154376788

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 59.7% of the total. Reporting peaked in 2019 at $329 and has fallen 74.9% since, to $83 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in MO, where the typical reported total is $2,673.

$1,445in general payments, 2019–2025

Across 97 payments — averaging $14.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$863
  • Collegium Pharmaceutical, Inc.$186
  • Amgen$114
  • Valinor Pharma, LLC$66
  • Novartis$59
  • Redhill Biopharma Inc.$49
  • plus $109 from 7 others

What the payments were for

  • Food & beverage$1,445100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,445 in reported general payments places this provider in the 30th percentile of 27 interventional pain medicine providers in Missouri.

See all interventional pain medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$33,530
Medicare patients
33
Services billed
2,090

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen787$25,420
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen574$18,759
Xtampza ErOxycodone Myristate38$15,379
MovantikNaloxegol Oxalate18$9,081
Naloxone Hcl65$3,596
Buprenorphine19$3,534
Lidocaine35$3,311
Oxycodone Hcl128$1,690
Gabapentin124$1,542
Cyclobenzaprine Hcl100$1,440
Baclofen74$1,332
Pregabalin48$616
Diclofenac Sodium18$597
Tizanidine Hcl60$572
Lubiprostone12$567

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$186$15,37938 claims
Redhill Biopharma Inc.Movantik$49$9,08118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 27 interventional pain medicine providers in Missouri.

Other interventional pain medicine in Brentwood

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →